Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) shares hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $63.96 and last traded at $63.96, with a volume of 0 shares traded. The stock had previously closed at $63.96.
RCDTF has been the topic of several recent research reports. Barclays reaffirmed an “equal weight” rating on shares of Recordati Industria Chimica e Farmaceutica in a research note on Tuesday, November 2nd. Zacks Investment Research cut shares of Recordati Industria Chimica e Farmaceutica from a “buy” rating to a “hold” rating in a research note on Friday, August 13th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Recordati Industria Chimica e Farmaceutica in a research note on Monday, November 1st. Finally, Oddo Bhf cut shares of Recordati Industria Chimica e Farmaceutica from a “neutral” rating to an “underperform” rating in a research note on Friday, July 30th. One research analyst has rated the stock with a sell rating and four have given a hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $64.00.
The firm’s 50-day moving average price is $59.87 and its two-hundred day moving average price is $57.55. The firm has a market capitalization of $13.20 billion, a PE ratio of 30.75 and a beta of 0.30. The company has a quick ratio of 1.11, a current ratio of 1.55 and a debt-to-equity ratio of 0.67.
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat.
Featured Story: Cost of equity and a company’s balance sheet
Receive News & Ratings for Recordati Industria Chimica e Farmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati Industria Chimica e Farmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.